Po Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Po Hu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin J. Wilkins
Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
2 shared publications - Liming Pei
Center for Mitochondrial and Epigenomic Medicine, Cardiovascular Institute, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
2 shared publications - Aidan Bauer
Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 shared publication - Christopher Petucci
University of Pennsylvania Cardiovascular Institute, Philadelphia, PA
1 shared publication Clarissa Shoffler
Cardiovascular Institute, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA
1 shared publicationDavid J. Goldberg
Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
- 7 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e039201
Comprehensive Multiomic Analysis Reveals Metabolic Reprogramming Underlying Human Fontan‐Associated Liver Disease
Background: The Fontan operation is the current standard of care for single‐ventricle congenital heart disease. Almost all patients with Fontan operation develop liver fibrosis at a young age, known as Fontan‐associated liver disease (FALD). The pathogenesis and mechanisms underlying FALD remain little understood, and there are no effective therapies. We aimed to present a comprehensive multiomic analysis of human FALD, revealing the fundamental biology and pathogenesis of FALD. Methods and Results: We recently generated a single‐cell transcriptomic and epigenomic atlas of human FALD using single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing, which uncovered substantial metabolic reprogramming. Here, we applied liquid chromatography–mass spectrometry–based untargeted metabolomics to unveil the metabolomic landscape of human FALD, using liver samples/biopsies from age‐ and sex‐matched donors and patients with FALD (n=12 per group). Results were integrated with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing and serum metabolomics data to present a comprehensive multiomic atlas of FALD.We discovered significant metabolic abnormalities in livers of adolescent patients with Fontan circulation, particularly amino acid metabolism, peroxisomal fatty acid oxidation, cytochrome P450 system, glycolysis, tricarboxylic acid cycle, ketone body metabolism, and bile acid metabolism. Integrated analyses with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing results unveiled potential underlying mechanisms of these metabolic changes. Comparison with serum metabolomics data indicate that liver metabolic reprogramming contributes to circulatory metabolomic changes in FALD. Furthermore, comparison with metabolomics data of human metabolic dysfunction–associated fatty liver disease and metabolic dysfunction–associated steatohepatitis highlighted dysregulated amino acid metabolism as a common metabolic abnormality. Conclusions: Our comprehensive multiomic analyses reveal new insights into the fundamental biology and pathogenesis mechanisms of human FALD.
- 7 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e039201
Open AccessComprehensive Multiomic Analysis Reveals Metabolic Reprogramming Underlying Human Fontan‐Associated Liver Disease
Background: The Fontan operation is the current standard of care for single‐ventricle congenital heart disease. Almost all patients with Fontan operation develop liver fibrosis at a young age, known as Fontan‐associated liver disease (FALD). The pathogenesis and mechanisms underlying FALD remain little understood, and there are no effective therapies. We aimed to present a comprehensive multiomic analysis of human FALD, revealing the fundamental biology and pathogenesis of FALD. Methods and Results: We recently generated a single‐cell transcriptomic and epigenomic atlas of human FALD using single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing, which uncovered substantial metabolic reprogramming. Here, we applied liquid chromatography–mass spectrometry–based untargeted metabolomics to unveil the metabolomic landscape of human FALD, using liver samples/biopsies from age‐ and sex‐matched donors and patients with FALD (n=12 per group). Results were integrated with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing and serum metabolomics data to present a comprehensive multiomic atlas of FALD.We discovered significant metabolic abnormalities in livers of adolescent patients with Fontan circulation, particularly amino acid metabolism, peroxisomal fatty acid oxidation, cytochrome P450 system, glycolysis, tricarboxylic acid cycle, ketone body metabolism, and bile acid metabolism. Integrated analyses with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing results unveiled potential underlying mechanisms of these metabolic changes. Comparison with serum metabolomics data indicate that liver metabolic reprogramming contributes to circulatory metabolomic changes in FALD. Furthermore, comparison with metabolomics data of human metabolic dysfunction–associated fatty liver disease and metabolic dysfunction–associated steatohepatitis highlighted dysregulated amino acid metabolism as a common metabolic abnormality. Conclusions: Our comprehensive multiomic analyses reveal new insights into the fundamental biology and pathogenesis mechanisms of human FALD.
- 24 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (744) , eadk6213
Single-cell multiomics guided mechanistic understanding of Fontan-associated liver disease
The Fontan operation is the current standard of care for single-ventricle congenital heart disease. Individuals with a Fontan circulation (FC) exhibit central venous hypertension and face life-threatening complications of hepatic fibrosis, known as Fontan-associated liver disease (FALD). The fundamental biology and mechanisms of FALD are little understood. Here, we generated a transcriptomic and epigenomic atlas of human FALD at single-cell resolution using multiomic snRNA-ATAC-seq. We found profound cell type–specific transcriptomic and epigenomic changes in FC livers. Central hepatocytes (cHep) exhibited the most substantial changes, featuring profound metabolic reprogramming. These cHep changes preceded substantial activation of hepatic stellate cells and liver fibrosis, suggesting cHep as a potential first “responder” in the pathogenesis of FALD. We also identified a network of ligand-receptor pairs that transmit signals from cHep to hepatic stellate cells, which may promote their activation and liver fibrosis. We further experimentally demonstrated that activins A and B promote fibrotic activation in vitro and identified mechanisms of activin A’s transcriptional activation in FALD. Together, our single-cell transcriptomic and epigenomic atlas revealed mechanistic insights into the pathogenesis of FALD and may aid identification of potential therapeutic targets.
- 24 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (744) , eadk6213
Single-cell multiomics guided mechanistic understanding of Fontan-associated liver disease
The Fontan operation is the current standard of care for single-ventricle congenital heart disease. Individuals with a Fontan circulation (FC) exhibit central venous hypertension and face life-threatening complications of hepatic fibrosis, known as Fontan-associated liver disease (FALD). The fundamental biology and mechanisms of FALD are little understood. Here, we generated a transcriptomic and epigenomic atlas of human FALD at single-cell resolution using multiomic snRNA-ATAC-seq. We found profound cell type–specific transcriptomic and epigenomic changes in FC livers. Central hepatocytes (cHep) exhibited the most substantial changes, featuring profound metabolic reprogramming. These cHep changes preceded substantial activation of hepatic stellate cells and liver fibrosis, suggesting cHep as a potential first “responder” in the pathogenesis of FALD. We also identified a network of ligand-receptor pairs that transmit signals from cHep to hepatic stellate cells, which may promote their activation and liver fibrosis. We further experimentally demonstrated that activins A and B promote fibrotic activation in vitro and identified mechanisms of activin A’s transcriptional activation in FALD. Together, our single-cell transcriptomic and epigenomic atlas revealed mechanistic insights into the pathogenesis of FALD and may aid identification of potential therapeutic targets.